Teva Pharmaceutical Industries Ltd. $TEVA Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 2.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,864,594 shares of the company’s stock after buying an additional 73,410 shares during the period. Dimensional Fund Advisors LP’s holdings in Teva Pharmaceutical Industries were worth $86,240,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Legal & General Group Plc raised its holdings in Teva Pharmaceutical Industries by 6.8% during the fourth quarter. Legal & General Group Plc now owns 3,608,387 shares of the company’s stock worth $112,618,000 after purchasing an additional 228,189 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Teva Pharmaceutical Industries by 8.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,082,578 shares of the company’s stock valued at $33,506,000 after purchasing an additional 80,106 shares during the period. Norges Bank purchased a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at approximately $1,098,060,000. TD Asset Management Inc boosted its holdings in Teva Pharmaceutical Industries by 47.1% in the 4th quarter. TD Asset Management Inc now owns 369,023 shares of the company’s stock valued at $11,517,000 after purchasing an additional 118,075 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in Teva Pharmaceutical Industries during the 1st quarter worth approximately $9,126,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Transactions at Teva Pharmaceutical Industries

In other news, EVP Eliyahu Sharon Kalif sold 153,251 shares of the business’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total value of $5,457,268.11. Following the completion of the transaction, the executive vice president directly owned 172,184 shares of the company’s stock, valued at $6,131,472.24. The trade was a 47.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Amir Weiss sold 10,679 shares of the stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total value of $384,444.00. Following the sale, the chief accounting officer directly owned 20,016 shares in the company, valued at approximately $720,576. The trade was a 34.79% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 300,493 shares of company stock valued at $10,537,510 over the last three months. 0.54% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Piper Sandler increased their target price on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research note on Tuesday. Barclays upped their price objective on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Wall Street Zen cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. UBS Group raised their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Finally, Truist Financial boosted their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and a consensus price target of $42.00.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva reported second-quarter revenue of approximately $4.14 billion, ahead of consensus estimates of $4.02 billion. Innovative medicines grew 43% year over year in local-currency terms, helping offset weaker generics sales. Teva Delivers Strong Q2 Results and Raises Outlook
• Positive Sentiment: Management raised its 2026 revenue outlook to $16.5 billion-$16.9 billion and increased projections for its three key innovative brands, signaling confidence in the company’s branded-drug growth strategy. Teva Outlines Higher 2026 Revenue Outlook
• Positive Sentiment: UZEDY sales reached a record $77 million in the second quarter, up 43% year over year. Teva raised its 2026 UZEDY revenue forecast to $270 million-$290 million from $250 million-$280 million, supporting optimism about its long-acting injectable portfolio. UZEDY Record Q2 Net Sales
• Positive Sentiment: Piper Sandler reportedly forecast substantial potential appreciation for TEVA, adding to bullish sentiment following the results. Piper Sandler Forecasts Strong Price Appreciation
• Neutral Sentiment: Options activity was unusually elevated: traders bought about 23,688 calls on Wednesday, followed by roughly 27,659 puts on Thursday. The activity indicates heightened speculation but does not establish a clear directional signal. Unusually Large Options Trading
• Negative Sentiment: Second-quarter EPS of $0.02 missed the $0.08 consensus estimate, while acquisition-related costs and impairment charges contributed to a reported net loss of $576 million. Full-year EPS guidance of $1.91-$2.11 also remains below the $2.17 consensus estimate. Teva Q2 Earnings Lag Estimates

Teva Pharmaceutical Industries Trading Up 2.1%

Shares of TEVA opened at $35.45 on Friday. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. Teva Pharmaceutical Industries Ltd. has a 1-year low of $14.99 and a 1-year high of $37.35. The stock has a market cap of $40.76 billion, a price-to-earnings ratio of 59.09, a price-to-earnings-growth ratio of 3.67 and a beta of 0.86. The firm has a 50 day simple moving average of $33.22 and a 200-day simple moving average of $32.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $4.14 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.59% and a net margin of 4.08%. Equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.